A Randomized, Controlled, Open-label Clinical Trial With an Open-label Extension to Investigate the Safety of Vosoritide in Infants and Young Children With Achondroplasia at Risk of Requiring Cervicomedullary Decompression Surgery
Latest Information Update: 23 Dec 2022
At a glance
- Drugs Vosoritide (Primary)
- Indications Achondroplasia
- Focus Adverse reactions
- Sponsors BioMarin Pharmaceutical
- 20 Dec 2022 Planned End Date changed from 1 Dec 2026 to 1 Dec 2027.
- 20 Dec 2022 Planned primary completion date changed from 1 Dec 2026 to 1 Dec 2027.
- 26 Jul 2022 Status changed from recruiting to active, no longer recruiting.